According to the National Comprehensive Cancer Network guidelines, the Oncotype DX breast recurrence score tests could help personalize systemic adjuvant treatment of HR+/HER2- and node-negative BC patients with tumor size greater than 0.5 cm. Here, ERBB2 is linked to neoplasm.